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“I am surprised that some of the larger centers didn’t have the foresight
to try very early on to create the kind of resources that Alane’s been able
to create to study the problem,” said Greg Feero, an M.D. and Ph.D.
geneticist who oversees research at Maine-Dartmouth Family Medicine
Residency and is an associate editor of the Journal of the American
Medical Association.
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What makes the work—and associated treatment—even more
remarkable is that all of these studies emanated, not from a major
research university and hospital, but from a family medicine residency
based in Waterville, Maine (albeit one of the largest and most reputable
in New England).
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In just a few years, their work—with coauthors that include Colby
student researchers—has been published in the world’s most prestigious
journals in the field. O’Connor’s first paper (co-written with physician
William Alto) was published in 2011 in the American Journal of Obstetrics
and Gynecology and is a go-to reference for those treating pregnant
women with opioid addiction.
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O’Connor, who went on to earn a doctorate
in nursing practice at Vanderbilt and specializes in addiction treatment
in Maine, and O’Brien, a Harvard-educated biostatistician and chair
of Colby’s Mathematics and Statistics Department, have spearheaded
studies that have yielded important developments in the use of a drug
called buprenorphine, an opioid substitute used to suppress symptoms of
withdrawal and cravings from powerfully addictive opioids like heroin
and fentanyl, and sold commercially as Suboxone.
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By Gerry Boyle ’78

Together the pair has combined their broad
experience to produce groundbreaking
research that is changing the way
clinicians around the world treat pregnant
and opioid-addicted women and their
unborn children.
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An addiction specialist and
a statistician team up to
develop groundbreaking
treatment for opioidaddicted pregnant women
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A
BETTER
Way

Before she became an addictionmedicine specialist, Alane O’Connor
’96 studied environmental economics at
Colby, and for several years consulted
on pollution cleanup and nuclear waste
storage. Associate Professor of Statistics
Liam O’Brien first studied physics and
mathematics, eyed medical school, and
early on put his analytical skills to work for
a psychiatric hospital.

O’Connor, who has practiced at Maine-Dartmouth for 13 years, can date
her entry into this specialty to 2007, when a patient who was pregnant
confided that she was addicted to opioids and did not want to be on
methadone, the traditional choice for pregnant women. O’Connor and
her colleagues had been using buprenorphine on nonpregnant patients
and looked around to see what research had been done on treatment of
pregnant ones. “There was nothing. Zero,” O’Connor said. “We said,
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Associate Professor of Statistics Liam O’Brien, left, and Alane O’Connor ’96, doctor of nursing practice and addiction-medicine specialist, confer in O’Brien’s office at
Colby. O’Brien does statistical analysis of data O’Connor gleans from her Waterville-based practice, which focuses on women who are pregnant and addicted to opioids.

‘Alright. We’ll try to figure this out.’”
Fortunately for countless mothers and infants, she was
equipped in multiple disciplines to do just that. And when the
sophistication of the work outstripped her statistical analysis
chops, O’Brien stepped in.
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This wasn’t always the plan.
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O’Connor grew up in central Maine (she was an alpine
ski racer at Colby), majored in economics and minored in
mathematics, and was mentored by renowned environmental
economist Thomas Tietenberg. At Colby she did an economic
work-up of the potential labor impact of a proposed clearcutting ban, then went on to work for a major environmental
consulting firm in Boston. There she trained her analytical
eye on Superfund cleanups and major oil spills, among
other projects.
But after five years, O’Connor was ready for a change and
recalled the time she spent volunteering at the community

hospital in Farmington, Maine. “I really liked the idea of
service,” she said. “Making a difference in people’s lives.”
She earned her master’s degree in nursing practice at Boston
College, then returned to Maine to practice and stepped
into what would soon become the vortex of an overwhelming
public health problem—opioid addiction.
Spurred by rampant use of the highly addictive prescription
pain reliever OxyContin, the opioid problem swept the
country—especially rural areas. Maine soon ranked as one
of the worst states in opioid abuse and overdose death as
the drugs of choice expanded from prescription narcotics to
heroin and fentanyl.
It wasn’t long before pregnant women started presenting with
addiction issues, and Maine is now one of the top three states
(along with West Virginia and Vermont) in the rate of babies
born drug affected. Eight percent of babies born in Maine
last year were substance exposed. O’Connor found herself
treating more and more of these patients—and also saw their
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“All the data points I was collecting—this
was one of them,” Watson said. “That
cemented it for me. It was an incredible
experience.”
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Those results, which Watson so
meticulously gathered and recorded,
would be scrutinized by Alane
O’Connor ’96, a doctor of nursing practice
at Maine-Dartmouth Family Medicine
Residency and Watson’s mentor last

That was just one of the rewarding and
even life-changing experiences during her
internship last summer. Long interested
in children’s health, she considered
becoming a pediatric surgeon. Coming to
Colby from Yarmouth, Maine, outside of
Portland, she was aware of the scourge of
opioid addiction in the state.

In addition to working on the
groundbreaking head-circumference study,
she shadowed O’Connor as she met with
patients, listened to them discuss their
pregnancies—and their drug use. Watson
sat in with groups of new mothers, talked
to them about their lives. On one occasion
a mom asked her to hold her baby—and
for Watson, her goal became clearer. She
would become a pediatric hospitalist.
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“We had the baseline for a normal head
circumference,” Watson said, “so I had
a little bit of an idea as I saw the results
coming in.”

“I wasn’t surprised,” Watson said, “but I
was happy.”

And as she finished the 10-week intensive
internship, another piece was falling
into place.
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Before birth the infants had been exposed
through their opioid-addicted mothers
to buprenorphine, an alternative to
methadone, the more commonly used
opioid replacement. Methadone had been
linked to smaller head circumference—and
associated problems—in babies. The
effects of buprenorphine had not been
scrutinized.

The conclusion: for this
cohort of infants there was no relationship
between head circumference at birth and
the mother’s buprenorphine dose, nor
was there a relationship at birth between
head circumference and the severity of
withdrawal. The study—coauthored by
O’Connor, O’Brien, and Watson and being
considered for publication by the Journal
of Maternal-Fetal & Neonatal Medicine—
provided one more reason for pregnant
women with opioid addiction to be given
buprenorphine, not methadone.

Dartmouth Family Practice Residency in
Waterville, which led to O’Connor. That
turned into an opportunity to assist with
O’Connor’s research, and to shadow
doctors at MaineGeneral Medical Center
in Augusta. Now Watson’s plan is to take
a year to work and another year to prepare
for MCATs and apply to medical school.
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E

ven as she was still adding
the head-circumference
measurements for all 137
babies to the data set, Lilly
Watson ’20 liked the trend that
was emerging.

summer. The numbers
would then be subjected
to rigorous statistical
analysis by Liam O’Brien,
biostatistician and
chair of the Department
of Mathematics and
Statistics at Colby.
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A PATH FORWARD
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CHARTING

—Gerry Boyle ’78

Watson used DavisConnects’ “Handshake”
database to connect to the Maine-
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“

There was nothing. Zero.
We said, ‘Alright. We’ll try
to figure this out.’”
—Alane O’Connor ’96 on the
dearth of research on treatment
for pregnant and drug-addicted
patients when the opioid epidemic
began to take off in Maine more
than a decade ago.
newborns suffering from withdrawal and the possibility of
longer-term effects.
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It’s a thorny health problem, complicated by social stigma,
a large number of uninsured patients, the potential state
intervention from child protective services due to drug use
during pregnancy, and the availability of buprenorphine,
also known as Suboxone, on the street. Women fear losing
custody of their infants if they seek addiction treatment
during pregnancy, so many attempt to acquire buprenorphine
from other sources. They see others who have used “subs”
during pregnancy and their babies seem fine, O’Connor said.
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“So they may think ‘I’ll just take this drug off the street.’
In reality, that is a potentially dangerous option as the
withdrawal syndrome infants experience after birth is very
treatable, but only if we know to look for it.”
Because withdrawal doesn’t peak until 72 hours after birth,
O’Connor worries about newborns that might be sent home
too early, since untreated withdrawal in infants can have
catastrophic consequences.

Pregnant women in addiction treatment also experience
significant stigma and pressure to get off all opioids during
pregnancy—including buprenorphine—but in utero
withdrawal can cause complications, including fetal demise,
she said. Keeping these patients on buprenorphine and
getting them into intensive counseling with close obstetrical
follow-up is by far the safest option, O’Connor said. “Most
women are terrified at their first visit, but I work hard to
make them feel that this is a safe place in their otherwise
entirely chaotic lives,” she said.
That trust is key, not only to the welfare of individual
patients, but also for the far-reaching clinical studies, Feero
said. “I don’t think she could achieve what she has been
able to achieve without a strong bond between her and the
patients she cares for. She’s incredibly dedicated to them.”
Said Lilly Watson ’20, who spent last summer as an intern
with O’Connor and sat in on meetings with patients where
drug use was discussed, “It’s more of a conversation than
an inquisition.”
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O’Brien grew up in a tough suburb of Denver and excelled
in high school academics. With encouragement from his
mother and his teachers, he applied to and was accepted to
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Feero introduced O’Connor to O’Brien, who consults
on everything from autism to housing discrimination to
school nutrition to validating psychological assessment
tools. O’Brien’s path to biostatistics was in some ways just as
indirect as O’Connor’s was to medicine, and the experiences
and interests he developed along the way would help create a
research team that punches far beyond its weight.

O’Brien was accepted to the doctoral program in biostatistics
at the university’s T.H. Chan School of Public Health.
Through the NIH psychiatric training grant, he was able to
work in the genetics lab at Massachusetts General Hospital,
followed by a stint at the Massachusetts Mental Health
Center, consulting for the psychiatrists there. Ultimately,
O’Brien—who had not studied biology or statistics before
Harvard—graduated with a doctorate in biostatistics and
a minor in psychiatric epidemiology, with an emphasis on
maternal and child health.
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So she and Alto did just that, publishing the seminal
article in 2011 on the management of women treated with
buprenorphine during pregnancy. But there were many
deeper questions to be answered. And O’Connor knew it
was time to bring in a research partner who could glean the
answers from the growing and unprecedented data set that
was being collected at her practice.

He considered medical school but thought that with his math
skills perhaps he could find a way to make a difference at a
broader public health level. O’Brien had done an internship
at the University of Colorado’s University Hospital as an
undergraduate and later identified a training program at
Harvard funded by the National Institutes of Health that
focused on biostatistics in psychiatry.
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She also knew that buprenorphine can be prescribed in a
doctor’s office, while methadone, dispensed through the
identifiable clinics, required pregnant women to be exposed
to public scrutiny. The prospect of running that gauntlet
could lead some women to deny drug use, to buy drugs on the
street, or to try to quit mid-pregnancy, exposing the unborn
child to serious physiological stresses. “Somebody had to
write this,” O’Connor said.

—Associate Professor of Statistics Liam O’Brien
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At the time, a dozen years ago, the preferred opioid substitute
was methadone, which was dispensed at clinics across Maine
and the country. As a result, the literature was scant about
buprenorphine effectiveness. But O’Connor had observed
that buprenorphine, used as she prescribed, resulted in fewer
medical complications for the women than with methadone,
and that infants experienced milder withdrawal symptoms.

“

You make a mistake and somebody
reads that paper and it either leads
them down a wrong research avenue,
or in some cases it could cause a
doctor to make a recommendation
that’s wrong. In the extreme case—it
sounds awful but it’s true—it could
kill somebody.”
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O’Connor put this knowledge to use in rural Maine, which
was emerging as one of the epicenters of the opioid crisis. She
and her colleagues serve a largely working-class population,
and many of those patients—including some 400 who were
pregnant—were entangled in addiction. O’Connor and her
colleagues decided then that “This is not somebody else’s
problem. This is our problem,” she said.
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She went back to school, earning her Vanderbilt doctorate
and working to hone her understanding of the economic
forces that drive the ways healthcare is provided. She also
considered how individual cases can be folded into data that
can result in more effective treatment for countless patients,
not only her own.

the Colorado School of Mines, which specializes in earth
sciences and engineering. As an undergraduate, he majored
in mathematics and physics and again excelled, expected to
graduate and find a job. When an advisor suggested graduate
school, his reaction was, “What are you talking about? I can’t
afford graduate school.” His advisor replied, “‘No, they’re
going to pay you.’”
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As a clinician, O’Connor was dedicated to treating individual
patients, but her economics background left her looking
for ways to have broader impact. “I knew that to make a
meaningful difference in healthcare, I needed more skills,
research skills, M.B.A.-type skills. How to think about health
policy, how to look at legislation, how to look at systems
of care.”

“I see the work with Alane as related to that because I see
addiction research as an important piece of psychiatric
research,” O’Brien said.
The perfect match on paper turned out to be just that.
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It’s an oversimplification to say that O’Brien’s role is to work
with the numbers. In fact, his analysis begins, not with
numbers, but with careful consideration of the words used
to express the question being asked. “I have to translate
the words used by the researcher into the appropriate data
analysis, so I need to know how to bridge that divide,”
he said.
O’Brien first translates the question into the variables that
will need to be considered, and then considers what types
of variables they are. Is it a binary variable, like are you on
buprenorphine or not? Or is the variable on a continuum,
like the babies’ gestational age or birth weight, that would
mean analysis of a variable that spans an interval. “That
dictates the type of statistical test I would start to think
about,” he said.
The catch, O’Brien said, is that the conditions attached to
the tests have to be satisfied. “If they are, great. I run the test
and I give her the results.”
If not? The question may have to be rephrased or refocused.
And working with O’Connor, that discussion is less
complicated than it can be. “Alane is great because she does
understand the statistics side more than other researchers
that I work with,” O’Brien said. “She can understand when
I tell her, ‘We need to look at other confounders.’ No other
researcher I work with understands my concerns as well as
she does. She understands what you can or can’t say with
the data.”
Some studies are more complicated than others. The
head-circumference study, the most complex statistical
analysis thus far, required that O’Brien generate “bootstrap
percentiles,” which call for data to be resampled over and
over (in this case one million times) to produce a simulated
data set of babies exposed to buprenorphine so that it could
be used as a proxy for the population of babies in Maine who
had been exposed. In that case, and others, he had to explain
his process to the peer reviewers so they were satisfied that
the conclusions were sound.
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And O’Brien has to be satisfied as well, in terms of
data integrity and ethics. In the case of buprenorphine,
a statistical stretch or muddy conclusion could have
dangerous results.
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“You make a mistake and somebody reads that paper and it
either leads them down a wrong research avenue, or in some
cases it could cause a doctor to make a recommendation that’s
wrong,” he said. “In the extreme case—it sounds awful but
it’s true—it could kill somebody.”
His biostatistics and his maternal and child health
background reinforced the importance of the work of the
buprenorphine study, which is affecting the lives of countless
women and children. “I care a lot about this project,” said
O’Brien, who also is adjunct faculty of the University of New
England College of Graduate and Professional Studies. “I

The Findings
O’Brien and O’Connor, with coauthors, have collaborated
on papers that have been published in the world’s most
prestigious addiction-medicine journals almost every year
since 2011. Their conclusions:
Women who are able to access addiction treatment early in
pregnancy were more likely to remain in treatment a year after
giving birth—Journal of Substance Abuse Treatment
There is no need to limit or reduce buprenorphine dosing
during pregnancy to prevent adverse outcomes in infants
—European Addiction Research
Breastfeeding appears safe in infants exposed to
buprenorphine during pregnancy, and an integrated obstetric
and addiction treatment program reduces the barriers that
many women in recovery encounter with breastfeeding
—Journal of Midwifery & Women’s Health
Marijuana use in the third trimester does not complicate
pregnancy or the delivery process for infants exposed to
buprenorphine during pregnancy but may have an impact on
the severity of infant withdrawal syndrome
—Drug and Alcohol Dependence
When compared to female infants, male infants were more
likely to have severe withdrawal syndrome after exposure to
buprenorphine during pregnancy—Journal of Perinatal Medicine
Concurrent exposure to antidepressants and buprenorphine
during pregnancy has been associated with a longer duration
of infant withdrawal symptoms
—Journal of Maternal-Fetal & Neonatal Medicine
Buprenorphine, unlike methadone, does not appear to be
associated with reduced head circumference at birth (and
related potential cognitive problems)—Journal of MaternalFetal & Neonatal Medicine
work on all kinds of stuff. People come up to me, they want
me to work on school nutrition data, they want me to work on
sleep data. You name it, I’ll try to help with it. But this is the
one that I’m most interested in by far.”
The addiction-medicine world is interested as well. The
Maine studies, and others, supporting the safety and
effectiveness of buprenorphine have caused the drug to be
designated by the American College of Obstetricians and
Gynecologists and the World Health Organization as a
first-line treatment along with methadone, rather than as
a second choice, O’Connor said. Increasingly, women are
becoming aware of its benefits for infants and are preferring
it to methadone.
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The Maine-Dartmouth Residency has become one of the
leading centers for addiction medicine, and Feero attributed
much of that progress to O’Connor and her clinical care and
research instincts. O’Connor is sought after to present at
national conferences, and the resident physicians are benefiting
from her knowledge, insight, and experience.
O’Connor, meanwhile, said that while it’s imperative that
the buprenorphine studies are disseminated to the medical
community at large, she still loves her one-on-one work with
patients, providing the right medication so they are stabilized

enough emotionally and physically to work on re-establishing
a normal life. A small number of mothers have tapered off
opioids entirely. Some have been referred to a higher level of
care. Some did not survive the disease. “The vast majority are
still with us,” she said.

instagram.com/colbycollege

And women and infants are the bottom line.

Recently a patient returned to O’Connor’s office with her
six-year-old daughter. The woman had been pregnant with the
child and addicted when she first came for treatment. Now,
with buprenorphine and very hard work, she was off opioids
entirely and her daughter was healthy. O’Connor said they
hugged and cried before the woman left to continue her drugfree life.
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